Phaseline

Companies › Technophage

Technophage: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Neurology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Eletriptan Hydrobromide
Serotonin 1f (5-HT1f) receptor agonist; Serotonin 1b (5-HT1b) receptor agonist; Serotonin 1d (5-HT1d) receptor agonist
HTR1F, HTR1B, HTR1DPhase 1Acute Spinal Cord Injury (SCI)Dec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06677229Eletriptan HydrobromidePhase 1Acute Spinal Cord Injury (SCI)NeurologyDec 2026

Targets

HTR1F (1) HTR1B (1) HTR1D (1)

Companies with the same targets

Leukos Biotech UCB BIOSCIENCES Zogenix

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.